Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics
about
Dynamic Transmission Economic Evaluation of Infectious Disease Interventions in Low- and Middle-Income Countries: A Systematic Literature ReviewA systematic review of modelling approaches in economic evaluations of health interventions for drug and alcohol problemsEstimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis.Acceptability of HIV Pre-exposure Prophylaxis (PREP) Among People Who Inject Drugs (PWID) in a Canadian Setting.Tailored combination prevention packages and PrEP for young key populations.Awareness and low uptake of post exposure prophylaxis for HIV among clinical medical students in a high endemicity setting.Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access.HIV Treatment and Prevention: A Simple Model to Determine Optimal InvestmentModeling and Cost-Effectiveness in HIV Prevention.Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection.Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa.Pre-exposure prophylaxis (PrEP) for people who inject drugs: reconciling community views and biomedical advances.Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States.Improving the effectiveness and delivery of pre-exposure prophylaxis (PrEP) to people who inject drugs.'PrEP is not ready for our community, and our community is not ready for PrEP': pre-exposure prophylaxis for HIV for people who inject drugs and limits to the HIV prevention response.PrEP Implementation Science: State-of-the-Art and Research Agenda.HIV and adolescents: focus on young key populations.Cost-effectiveness of alternative strategies for provision of HIV pre-exposure prophylaxis for people who inject drugs.In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs?Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand
P2860
Q28072167-D89A6DF6-A944-463F-B65C-EFA48F1DFE28Q28072735-8A359741-C212-42C4-A101-42C936B1FA06Q33724701-1BAC7EA0-2F5B-4E7E-A3D4-62393B5C3110Q35044505-A8D9F70C-04AC-41EC-A694-48D29DA4C388Q35131207-E3496D8F-7CB0-4236-A6E2-A7248CF6FB01Q35834660-7C940293-46E8-428E-8FFF-EF9DC87DC64BQ35875746-47C4D4A3-48D4-48F7-A60B-A0B68B903E6BQ36642710-C6358A8D-3BAE-46F4-9FEB-8C2AAAAE5DBFQ36654828-EC82E40D-8FC7-4ADB-84BC-160448DA7513Q36816564-99B01F9F-A6A5-40C6-95E2-E19292468778Q37298218-883DFBED-94A2-4068-A649-5276ED2F3FF2Q39036221-E2CFE9DA-1E64-4557-A889-98CA87B83CF2Q39825094-B63FDFAC-33C5-4D84-AE4F-E026BA6F73B2Q40412012-DC3BD82B-7C3C-4A33-BC47-7878E996F3B4Q42104687-DF29025C-CFE7-4ED4-8405-C7114F04AB65Q43241737-8F3EF67E-6D4C-4EFE-9E47-4D13AC612D11Q46119171-893915A3-EFAE-493F-ABE7-252A26DB631FQ48537541-86985DC0-6B18-4F21-AF99-64713882323AQ50051642-EB5DFCF1-95E3-4E65-A10A-865335D53823Q57178454-EE9F8A10-679D-459A-90CC-804CCAB62AFD
P2860
Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Effectiveness and cost effecti ...... g users in mixed HIV epidemics
@ast
Effectiveness and cost effecti ...... g users in mixed HIV epidemics
@en
Effectiveness and cost effecti ...... g users in mixed HIV epidemics
@nl
type
label
Effectiveness and cost effecti ...... g users in mixed HIV epidemics
@ast
Effectiveness and cost effecti ...... g users in mixed HIV epidemics
@en
Effectiveness and cost effecti ...... g users in mixed HIV epidemics
@nl
prefLabel
Effectiveness and cost effecti ...... g users in mixed HIV epidemics
@ast
Effectiveness and cost effecti ...... g users in mixed HIV epidemics
@en
Effectiveness and cost effecti ...... g users in mixed HIV epidemics
@nl
P2093
P2860
P3181
P1433
P1476
Effectiveness and cost effecti ...... g users in mixed HIV epidemics
@en
P2093
Douglas K Owens
Margaret L Brandeau
Sabina S Alistar
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0086584
P407
P577
2014-01-01T00:00:00Z